Kidney cancer represents approximately 4% to 5% of all cancer cases, with an estimated 646,960 individuals currently living with kidney and renal pelvis cancer in the United States. The most prevalent form is renal cell carcinoma (RCC), which accounts for about 90% of all kidney cancer diagnoses. RCC encompasses several subtypes, including clear cell, papillary, chromophobe, collecting duct, renal medullary carcinoma, translocation-associated, and unclassified variants. The disease is about twice as common in men as in women, according to the Kidney Cancer Association. The global market for kidney cancer drugs, valued at $7.31 billion in 2025, is projected to grow to $11.07 billion by 2032, based on a report from Coherent Market Insights.
The company we are profiling today is Xencor Inc. (XNCR), which is developing a novel drug for clear cell renal cell carcinoma.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.